PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Declining payables indicates faster supplier payments but reduces free financing. Howard Marks would verify liquidity remains adequate.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.66%
Declining current liabilities reduces short-term financial pressure. Seth Klarman would see this as improving liquidity position.
-14.44%
Declining long-term debt reduces leverage risk. Howard Marks would see this as improving financial stability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.44%
Declining total non-current liabilities reduces long-term leverage risk. Benjamin Graham would see this as strengthening the balance sheet.
No Data
No Data available this quarter, please select a different quarter.
-20.71%
Declining total liabilities strengthens the balance sheet. Howard Marks would see this as reducing financial risk.
No Data
No Data available this quarter, please select a different quarter.
7.46%
5-10% yoy – moderate improvement. Seth Klarman notes normal reinvestment if returns are decent.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Declining other equity items simplifies the capital structure. Benjamin Graham would favor this reduction in complexity.
20.74%
Equity growth ≥ 10% yoy – a strengthening net worth. Warren Buffett checks if the ROE is healthy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.44%
Declining total debt reduces leverage risk. Seth Klarman would see this as improving financial stability and flexibility.
-14.48%
Declining net debt indicates improving liquidity or deleveraging. Howard Marks would see this as strengthening financial position.